Desenvolvimento de um bioproduto de uso tópico vaginal contendo óleo essencial de origanum vulgare para o tratamento da candidíase vaginal.

Abstract

Vulvovaginal candidiasis (VVC) is a common vaginal fungal infection, the main etiologic agent is Candida albicans, commonly characterized by vulvar itching, burning, painful urination and vaginal discharge. Worldwide prevalence and epidemiological data are rare and imprecise because they are mostly obtained from self-reports and diagnoses by the local general practitioner. There is a wide spectrum of factors that can predispose the disease, such as type 2 diabetes mellitus, immunosuppression regimens, antibiotic therapy, behavioral factors such as the use of oral contraceptives and intrauterine devices. The diagnosis is usually made clinically, based on the signs and symptoms presented by the patient, treatment in the vast majority of cases is performed only in symptomatic patients. Usually the drug therapy used are azole antifungals, both orally and topically, despite being effective, over the years they started to show resistance. For this reason, this project aims to prove the antifungal activity of an intravaginal topical bioproduct developed from the essential oil of Origanum vulgare with natural components that is not as aggressive as the conventional treatment to individuals who have vaginal candidiasis. The essential oil was evaluated by Gas Chromatography coupled to Mass Spectrometry (GC-MS), presenting its main constituents as found in the literature, the eggs were analyzed for organoleptic, physicochemical and antifungal action. After opting for the Novata® grease base, which presented better advantages such as speed in production, better presentation and without the need to incorporate preservatives. The antifungal action was analyzed by the disk-diffusion method in agar, obtaining satisfactory results in relation to OEO, the bioproduct and fluconazole. Although the bioproduct presents sensitive results against strains of Candida albicans, it is necessary to carry out new tests in vitro and in vivo, against other Candida species, cytotoxicity tests and, if necessary, the exchange of base.